Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease

Más betegség

• Human immunodeficiency virus (HIV) infection (seropositive at Screening)
• Seropositive for hepatitis B (HBV) or hepatitis C (HCV) at Screening
• Clinically significant cardiac, liver, or renal disease
• Known allergy or possible allergy to either ARO-MAPT-SC or to its excipients
  • Note: Additional inclusion/exclusion criteria may apply per protocol.

Egyéb

• Blood pressure outside of specified range in the protocol
• Intellectual disability or significant behavioral neuropsychiatric manifestation
• Any contraindications to lumbar puncture

• Body mass index between 18.0 and 35.0 kilograms (kg)/square meter (m\^2) at Screening
• Not pregnant or breast-feeding
• Able and willing to provide written informed consent prior to the performance of any study specific procedures
• Participants of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later; participants must not donate sperm or eggs during the study and for at least 90 days following the end of the study or last dose of study drug whichever is later
• Adults aged 50 to 80 years of age with a clinical diagnosis of early AD and plasma, CSF, or imaging biomarkers consistent with the diagnosis
• If participant is on non-disease-modifying AD medications, the doses must be stable for ≥weeks prior to Screening.
  • Participants with early AD are not required to be on AD medications.
  • Participants previously treated or currently receiving anti-amyloid therapies, including lecanemab and donanemab, are not eligible.
• Have a reliable and competent caregiver or trial partner who is ≥18 years of age, able and willing to accompany the participant to study visits involving informant-based assessments, to be available to site staff by telephone as needed, and in the opinion of the Investigator, be sufficiently familiar with the participant throughout the study in order to provide accurate and reliable information relevant to study outcome measures